A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain : a Delphi consensus panel study
Isla, Dolores (Instituto de Investigación Sanitaria de Aragón)
Felip, Enriqueta (Hospital Universitari Vall d'Hebron)
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid))
Insa, Amelia (Hospital Clínic Universitari (València))
Majem Tarruella, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Remon, Jordi (CIOCC HM Nou Delfos)
Trigo, Jose M. (HC Marbella-Hospital International)
Castro, Javier de (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	This Delphi panel study assessed the level of consensus between medical oncologists on the clinical management of patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC). A modified two-round Delphi approach was used. A scientific committee comprised of medical oncologists developed an online questionnaire. Delphi panel experts rated their level of agreement with each questionnaire statement on a 9-point Likert scale. The questionnaire included 36 statements from 3 domains (clinical management of early-stage NSCLC: 15 statements; role of adjuvant therapy in early-stage NSCLC: 9 statements; and role of adjuvant therapy in early-stage NSCLC with sensitizing EGFR mutation: 12 statements). In round 1, consensus was reached for 24/36 statements (66. 7%). Nine statements that did not achieve consensus after the first round were evaluated in round 2, and none of them reached consensus. Overall, 84. 4% of the panelists agreed that EGFR mutation testing should be done after surgery. Consensus was not achieved on whether the implementation of EGFR mutation testing in resected early-stage NSCLC could limit the use of adjuvant osimertinib. The panelists recognized the rationale for the use of osimertinib in the adjuvant scenario (88%) and 72% agreed that it may change the treatment paradigm in stage IB-IIIA EGFR-mutated NSCLC. Consensus was not reached on the inconvenience of prolonged duration of osimertinib. This Delphi study provides valuable insights into relevant questions in the management of early-stage EGFR-mutated NSCLC. However, specific issues remain unresolved. The expert consensus emphasizes the role of adjuvant treatment with osimertinib in this scenario.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adjuvant ; Consensus ; Delphi method ; EGFR-mutated ; Non-small cell lung cancer (NSCLC) ; Osimertinib
Publicat a:	Clinical & translational oncology, Vol. 25 Núm. 1 (january 2023) , p. 283-291, ISSN 1699-3055

DOI: 10.1007/s12094-022-02941-5
PMID: 36168085

9 p, 389.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats